Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)–associated membranous nephropathy

Spain, Rebecca; Andeen, Nicole K.; Gibson, Pamela Church; Samuels, Mary H.; Morris, Cynthia D.; Solomon, Andrew; Solomon, Richard; Waslo, Carin S.; Avasare, Rupali S.

doi:10.1016/j.kint.2021.10.010

Cited by 42 publications

(39 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Multiple medications are described to cause MN, comprising 6.6-14% of total MN in prior studies (122)(123)(124). Drug-induced MN was reported with therapy with gold salts, penicillamine, bucillamine, captopril, non-steroidal anti-inflammatory drugs (NSAIDs), selective COX-2 inhibitors, tiopronin, trimethadione, and lipoic acid (74,123). NSAIDs are currently the leading offender and this form of MN is often reversible, remitting with discontinuation of the offending drug (125).…”

Section: Medications Inducing Membranous Nephropathymentioning

confidence: 99%

How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy

2021

View full text Add to dashboard Cite

The identification of the major target antigen phospholipase A2 receptor (PLA2R) in the majority of primary (idiopathic) cases of membranous nephropathy (MN) has been followed by the rapid identification of numerous minor antigens that appear to define phenotypically distinct forms of disease. This article serves to review all the known antigens that have been shown to localize to subepithelial deposits in MN, as well as the distinctive characteristics associated with each subtype of MN. We will also shed light on the novel proteomic approaches that have allowed identification of the most recent antigens. The paradigm of an antigen normally expressed on the podocyte cell surface leading to in-situ immune complex formation, complement activation, and subsequent podocyte injury will be discussed and challenged in light of the current repertoire of multiple MN antigens. Since disease phenotypes associated with each individual target antigens can often blur the distinction between primary and secondary disease, we encourage the use of antigen-based classification of membranous nephropathy.

show abstract

Section: Medications Inducing Membranous Nephropathymentioning

confidence: 99%

How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy

2021

View full text Add to dashboard Cite

show abstract

“…Finally, a recent study by Spain et al [ 27 ] found that in patients administered lipoic acid for different conditions, high-grade proteinuria could appear. These patients may have NELL-1-associated MN, and the discontinuation of lipoic acid could result in proteinuria remission.…”

Section: Introductionmentioning

confidence: 99%

New antigens involved in membranous nephropathy beyond phospholipase A2 receptor

Salvadori¹,

Tsalouchos²

2022

WJN

View full text Add to dashboard Cite

When the physiopathology of membranous nephropathy was first described, almost 30% of cases were recognized to be secondary to well-known diseases such as autoimmune diseases, tumors or infections. The remaining 70% cases were called primary membranous nephropathy as the exact mechanism or pathogenic factor involved was unknown. The discovery of the M type phospholipase A2 receptor and thrombospondin type 1 domain containing 7A as causative antigens in these “so called” primary membranous nephropathies provided new insights into the effective causes of a large proportion of these cases. Novel techniques such as laser microdissection and tandem mass spectrometry as well as immunochemistry with antibodies directed against novel proteins allowed the confirmation of new involved antigens. Finally, using confocal microscopy to localize these new antigens and immunoglobulin G and Western blot analysis of serum samples, these new antigens were detected on the glomerular membrane, and the related antibodies were detected in serum samples. The same antigens have been recognized in some cases of secondary membranous disease due to autoimmune diseases, tumors and infections. This has allowed examination of the relationship between antigens in primary membranous nephropathy and their presence in some secondary nephropathies. The aim of this study is to describe the characteristics of the new antigens discovered and their association with other diseases.

show abstract

“…PLA2R is an antigen related to the etiology of iMN and has been proved important in proteinuria remission and relapse [ 7 ]. Other antigens such as THSD7A, exostosin1/exostosin2, NELL1, semaphorin3B, and protocadherin have then been discovered [ 8 , 9 ].…”

Section: Introductionmentioning

confidence: 99%

Non-diabetic urine glucose in idiopathic membranous nephropathy

Liu

Zuo

et al. 2022

Renal Failure

View full text Add to dashboard Cite

This study aims to analyze the characteristics of idiopathic membranous nephropathy (iMN) with nondiabetic urine glucose during the follow-up. We retrospectively analyzed the data of 1313 patients who were diagnosed iMN. The prevalence of nondiabetic urine glucose during follow-up was 10.89%. There were significant differences between the patients with nondiabetic urine glucose and those without urine glucose in gender, hypertension ratio, proteinuria, N-acetyl-β-glucosaminidase, retinol binding protein, serum albumin, serum creatinine (Scr), cholesterol, triglyceride and positive anti-phospholipase A2 receptor antibody ratio, glomerular sclerosis ratio, acute and chronic tubular injury lesion at baseline. To exclude the influence of the baseline proteinuria and Scr, case control sampling of urine glucose negative patients was applied according to gender, baseline proteinuria and Scr. The proteinuria nonremission (NR) ratio was 45.83 versus 12.50% of the urine glucose positive group and case control group. Partial remission (PR) ratio of the two groups was 36.46 versus 23.96% and complete remission (CR) ratio was 19.79% versus 63.54%, respectively. Patients with urine glucose had higher risk of 50% estimated glomerular filtration rate (eGFR) reduction. Cox regression showed that urine glucose and baseline Scr were risk factors of 50% reduction of eGFR. Urine glucose remission ratio of the patients with proteinuria NR, PR, and CR was 13.33, 56.25, and 94.73% ( p < 0.005). Patients who got urine glucose remission also had better renal survival. In conclusion, non-diabetic urine glucose was closely related to proteinuria. It could be applied as a tubular injury marker to predict renal function.

show abstract

Lipoic acid supplementation associated with neural epidermal growth factor-like 1 (NELL1)–associated membranous nephropathy

Cited by 42 publications

References 23 publications

How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy

How Times Have Changed! A Cornucopia of Antigens for Membranous Nephropathy

New antigens involved in membranous nephropathy beyond phospholipase A2 receptor

Non-diabetic urine glucose in idiopathic membranous nephropathy

Contact Info

Product

Resources

About